The NYU School of Medicine is collaborating with technology company Tempus with the aim of improving outcomes for pancreatic cancer patients through advanced analysis of NYU’s genomic data. As part of the research collaboration, Tempus will work directly with the medical school’s newly established pancreatic cancer center. NYU Langone has collected data from roughly 500 patients with pancreatic cancer that Tempus will structure and analyze using techniques such as optical natural language processing and the company’s machine learning platform. The researchers hope to uncover patterns that predict how patients will respond to different pancreatic cancer treatments. “Generating and analyzing the data may provide evidence for alternative treatment choices where patients have seen little benefit with the current standard of care,” said Eric Lefkofsky, Tempus’ co-founder and CEO.